Novel Mental Health Next Generation Technology to Advance the Study and Therapeutic Use of Medical Cannabis

EHVVF Partners with MedReleaf to Optimize Therapeutic Potential of Medical Cannabis Products Novel Mental Health Next Generation Technology to Advance the Study and Therapeutic Use of Medical Cannabis.

“By 2024, more than 450,000 Canadian patients will be prescribed medical cannabis, creating a market worth more than $1.3 billion, according to Health Canada estimates,” said Prateek Dwivedi, President and CEO of Ehave. “This large and emerging industry is in desperate need of a technology platform to capture and deliver reliable clinical data to satisfy the needs of patients, clinicians, regulators, and payors…”

THE EHAVE, INC AND MEDRELEAF PARTNERSHIP:

Ehave, Inc., a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, and MedReleaf Corp., Canada’s premium medical cannabis licensed producer, announced that the companies have entered into a partnership to develop a branded MedReleaf app utilizing the Ehave Connect mental health informatics platform to advance the study and therapeutic use of medical cannabis. Ehave Connect enables developers, and ultimately prescribers, of medical cannabis to design and monitor treatment plans, track patient compliance, and verify treatment outcomes in a reliable and objective manner.

Together, Ehave and MedReleaf seek to validate and optimize the use of MedReleaf’s medical cannabis products as therapeutic treatments for various mental health conditions. Ultimately, it is anticipated that the MedReleaf App based on the Ehave Connect platform can be used to monitor every step of the medical cannabis treatment life cycle, from diagnosis and treatment planning to medication adherence and outcomes verification.